Cargando…

The COVID-19 Pandemic Has Had Negative Effects on Baseline Clinical Presentation and Outcomes of Patients with Newly Diagnosed Treatment-Naïve Exudative AMD

Purpose: To investigate whether the coronavirus disease 2019 (COVID-19) pandemic-associated postponement in care had effects on the baseline clinical presentation of patients with newly diagnosed treatment-naïve exudative neovascular age-related macular degeneration (AMD). Methods: We included the f...

Descripción completa

Detalles Bibliográficos
Autores principales: Borrelli, Enrico, Battista, Marco, Vella, Giovanna, Grosso, Domenico, Sacconi, Riccardo, Querques, Lea, Zucchiatti, Ilaria, Prascina, Francesco, Bandello, Francesco, Querques, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003286/
https://www.ncbi.nlm.nih.gov/pubmed/33803808
http://dx.doi.org/10.3390/jcm10061265
_version_ 1783671654081101824
author Borrelli, Enrico
Battista, Marco
Vella, Giovanna
Grosso, Domenico
Sacconi, Riccardo
Querques, Lea
Zucchiatti, Ilaria
Prascina, Francesco
Bandello, Francesco
Querques, Giuseppe
author_facet Borrelli, Enrico
Battista, Marco
Vella, Giovanna
Grosso, Domenico
Sacconi, Riccardo
Querques, Lea
Zucchiatti, Ilaria
Prascina, Francesco
Bandello, Francesco
Querques, Giuseppe
author_sort Borrelli, Enrico
collection PubMed
description Purpose: To investigate whether the coronavirus disease 2019 (COVID-19) pandemic-associated postponement in care had effects on the baseline clinical presentation of patients with newly diagnosed treatment-naïve exudative neovascular age-related macular degeneration (AMD). Methods: We included the first 50 consecutive patients referred within the COVID-19 pandemic with a diagnosis of treatment-naïve exudative neovascular AMD. Two groups of fifty consecutive patients with newly diagnosed neovascular exudative AMD presenting in 2018 and 2019 (control periods) were also included for comparisons. Results: Baseline visual acuity was statistically worse in patients referred during the COVID-19 pandemic period (0.87 ± 0.51 logarithm of the minimum angle of resolution (LogMAR)) as compared with both the “2019” (0.67 ± 0.48 LogMAR, p = 0.001) and “2018” (0.69 ± 0.54 LogMAR, p = 0.012) control periods. Data on the visual function after a loading dose of anti-vascular endothelial growth factor (VEGF) was available in a subset of patients (43 subjects in 2020, 45 in 2019 and 46 in 2018, respectively). Mean ± SD best corrected visual acuity (BCVA) at the 1-month follow-up visit after the third anti-VEGF injection was still worse in patients referred during the COVID-19 pandemic (0.82 ± 0.66 LogMAR) as compared with both the “2019” (0.60 ± 0.45 LogMAR, p = 0.021) and “2018” (0.55 ± 0.53 LogMAR, p = 0.001) control periods. On structural optical coherence tomography (OCT), the maximum subretinal hyperreflective material (SHRM) height and width were significantly greater in the COVID-19 pandemic patients. Conclusions: We demonstrated that patients with newly diagnosed treatment-naïve exudative neovascular AMD referred during the COVID-19 pandemic had worse clinical characteristics at presentation and short-term visual outcomes.
format Online
Article
Text
id pubmed-8003286
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80032862021-03-28 The COVID-19 Pandemic Has Had Negative Effects on Baseline Clinical Presentation and Outcomes of Patients with Newly Diagnosed Treatment-Naïve Exudative AMD Borrelli, Enrico Battista, Marco Vella, Giovanna Grosso, Domenico Sacconi, Riccardo Querques, Lea Zucchiatti, Ilaria Prascina, Francesco Bandello, Francesco Querques, Giuseppe J Clin Med Article Purpose: To investigate whether the coronavirus disease 2019 (COVID-19) pandemic-associated postponement in care had effects on the baseline clinical presentation of patients with newly diagnosed treatment-naïve exudative neovascular age-related macular degeneration (AMD). Methods: We included the first 50 consecutive patients referred within the COVID-19 pandemic with a diagnosis of treatment-naïve exudative neovascular AMD. Two groups of fifty consecutive patients with newly diagnosed neovascular exudative AMD presenting in 2018 and 2019 (control periods) were also included for comparisons. Results: Baseline visual acuity was statistically worse in patients referred during the COVID-19 pandemic period (0.87 ± 0.51 logarithm of the minimum angle of resolution (LogMAR)) as compared with both the “2019” (0.67 ± 0.48 LogMAR, p = 0.001) and “2018” (0.69 ± 0.54 LogMAR, p = 0.012) control periods. Data on the visual function after a loading dose of anti-vascular endothelial growth factor (VEGF) was available in a subset of patients (43 subjects in 2020, 45 in 2019 and 46 in 2018, respectively). Mean ± SD best corrected visual acuity (BCVA) at the 1-month follow-up visit after the third anti-VEGF injection was still worse in patients referred during the COVID-19 pandemic (0.82 ± 0.66 LogMAR) as compared with both the “2019” (0.60 ± 0.45 LogMAR, p = 0.021) and “2018” (0.55 ± 0.53 LogMAR, p = 0.001) control periods. On structural optical coherence tomography (OCT), the maximum subretinal hyperreflective material (SHRM) height and width were significantly greater in the COVID-19 pandemic patients. Conclusions: We demonstrated that patients with newly diagnosed treatment-naïve exudative neovascular AMD referred during the COVID-19 pandemic had worse clinical characteristics at presentation and short-term visual outcomes. MDPI 2021-03-18 /pmc/articles/PMC8003286/ /pubmed/33803808 http://dx.doi.org/10.3390/jcm10061265 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Borrelli, Enrico
Battista, Marco
Vella, Giovanna
Grosso, Domenico
Sacconi, Riccardo
Querques, Lea
Zucchiatti, Ilaria
Prascina, Francesco
Bandello, Francesco
Querques, Giuseppe
The COVID-19 Pandemic Has Had Negative Effects on Baseline Clinical Presentation and Outcomes of Patients with Newly Diagnosed Treatment-Naïve Exudative AMD
title The COVID-19 Pandemic Has Had Negative Effects on Baseline Clinical Presentation and Outcomes of Patients with Newly Diagnosed Treatment-Naïve Exudative AMD
title_full The COVID-19 Pandemic Has Had Negative Effects on Baseline Clinical Presentation and Outcomes of Patients with Newly Diagnosed Treatment-Naïve Exudative AMD
title_fullStr The COVID-19 Pandemic Has Had Negative Effects on Baseline Clinical Presentation and Outcomes of Patients with Newly Diagnosed Treatment-Naïve Exudative AMD
title_full_unstemmed The COVID-19 Pandemic Has Had Negative Effects on Baseline Clinical Presentation and Outcomes of Patients with Newly Diagnosed Treatment-Naïve Exudative AMD
title_short The COVID-19 Pandemic Has Had Negative Effects on Baseline Clinical Presentation and Outcomes of Patients with Newly Diagnosed Treatment-Naïve Exudative AMD
title_sort covid-19 pandemic has had negative effects on baseline clinical presentation and outcomes of patients with newly diagnosed treatment-naïve exudative amd
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003286/
https://www.ncbi.nlm.nih.gov/pubmed/33803808
http://dx.doi.org/10.3390/jcm10061265
work_keys_str_mv AT borrellienrico thecovid19pandemichashadnegativeeffectsonbaselineclinicalpresentationandoutcomesofpatientswithnewlydiagnosedtreatmentnaiveexudativeamd
AT battistamarco thecovid19pandemichashadnegativeeffectsonbaselineclinicalpresentationandoutcomesofpatientswithnewlydiagnosedtreatmentnaiveexudativeamd
AT vellagiovanna thecovid19pandemichashadnegativeeffectsonbaselineclinicalpresentationandoutcomesofpatientswithnewlydiagnosedtreatmentnaiveexudativeamd
AT grossodomenico thecovid19pandemichashadnegativeeffectsonbaselineclinicalpresentationandoutcomesofpatientswithnewlydiagnosedtreatmentnaiveexudativeamd
AT sacconiriccardo thecovid19pandemichashadnegativeeffectsonbaselineclinicalpresentationandoutcomesofpatientswithnewlydiagnosedtreatmentnaiveexudativeamd
AT querqueslea thecovid19pandemichashadnegativeeffectsonbaselineclinicalpresentationandoutcomesofpatientswithnewlydiagnosedtreatmentnaiveexudativeamd
AT zucchiattiilaria thecovid19pandemichashadnegativeeffectsonbaselineclinicalpresentationandoutcomesofpatientswithnewlydiagnosedtreatmentnaiveexudativeamd
AT prascinafrancesco thecovid19pandemichashadnegativeeffectsonbaselineclinicalpresentationandoutcomesofpatientswithnewlydiagnosedtreatmentnaiveexudativeamd
AT bandellofrancesco thecovid19pandemichashadnegativeeffectsonbaselineclinicalpresentationandoutcomesofpatientswithnewlydiagnosedtreatmentnaiveexudativeamd
AT querquesgiuseppe thecovid19pandemichashadnegativeeffectsonbaselineclinicalpresentationandoutcomesofpatientswithnewlydiagnosedtreatmentnaiveexudativeamd
AT borrellienrico covid19pandemichashadnegativeeffectsonbaselineclinicalpresentationandoutcomesofpatientswithnewlydiagnosedtreatmentnaiveexudativeamd
AT battistamarco covid19pandemichashadnegativeeffectsonbaselineclinicalpresentationandoutcomesofpatientswithnewlydiagnosedtreatmentnaiveexudativeamd
AT vellagiovanna covid19pandemichashadnegativeeffectsonbaselineclinicalpresentationandoutcomesofpatientswithnewlydiagnosedtreatmentnaiveexudativeamd
AT grossodomenico covid19pandemichashadnegativeeffectsonbaselineclinicalpresentationandoutcomesofpatientswithnewlydiagnosedtreatmentnaiveexudativeamd
AT sacconiriccardo covid19pandemichashadnegativeeffectsonbaselineclinicalpresentationandoutcomesofpatientswithnewlydiagnosedtreatmentnaiveexudativeamd
AT querqueslea covid19pandemichashadnegativeeffectsonbaselineclinicalpresentationandoutcomesofpatientswithnewlydiagnosedtreatmentnaiveexudativeamd
AT zucchiattiilaria covid19pandemichashadnegativeeffectsonbaselineclinicalpresentationandoutcomesofpatientswithnewlydiagnosedtreatmentnaiveexudativeamd
AT prascinafrancesco covid19pandemichashadnegativeeffectsonbaselineclinicalpresentationandoutcomesofpatientswithnewlydiagnosedtreatmentnaiveexudativeamd
AT bandellofrancesco covid19pandemichashadnegativeeffectsonbaselineclinicalpresentationandoutcomesofpatientswithnewlydiagnosedtreatmentnaiveexudativeamd
AT querquesgiuseppe covid19pandemichashadnegativeeffectsonbaselineclinicalpresentationandoutcomesofpatientswithnewlydiagnosedtreatmentnaiveexudativeamd